A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques

Journal of Chemical Information and Computer Sciences

Volumn 44, Issue 5, 2004, Pages 1857-1871

  Tsai, Keng Chang ^a   Lin, Thy Hou ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYSTS; COMPLEXATION; CONFORMATIONS; CRYSTAL STRUCTURE; ENZYMES; MOLECULAR STRUCTURE;

LIGANDS; MOLECULAR FIELD ANALYSIS; PHARMACOPHORE; STRUCTURE TEMPLATE;

ENZYME INHIBITION;

INTERSTITIAL COLLAGENASE; LIGAND; PROTEINASE INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

LIGANDS; MATRIX METALLOPROTEINASE 1; MODELS, MOLECULAR; PROTEASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 5444231462     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci049824g     Document Type: Article

References (42)

1. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
2. Leff, R. L. Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications Ann. N. Y. Acad. Sci. 1999, 878, 201-207.
3. Clark, I. M.; Rowan, A. D.; Cawston, T. E. Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr. Opin. Anti-inflammatory Immunomodulatory Invest. Drugs 2000, 2, 16-25.
4. Shlopov, B. V.; Lie, W. R.; Mainardi, C. L.; Cole, A. A.; Chubinskaya, S.; Hasty, K. A. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum. 1997, 40, 2065-2074.
5. Ahrens, D.; Koch, A. E.; Pope, R. M.; Steinpicarella, M.; Niedbala, M. J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 1996, 39, 1576-1587.
6. Blaser, J.; Triebel, S.; Maajosthusmann, U.; Rimisch, J.; Krahlmateblowski, U.; Freudenberg, W.; Fricke, R.; Tschesche, H. Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis. Clin. Chim. Acta 1996, 244, 17-33.
7. Peress, N.; Perillo, E.; Zucker, S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54, 16-22.
8. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Matin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nature Struct. Biol. 1999, 6, 217-221.
9. Knight, C. G.; Willenbrock, F.; Murphy, G. A. A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
10. Okada, Y.; Nagase, H.; Harris, E. D. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J. Biol. Chem. 1986, 261, 14245-14255.
11. Stams, T.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. W.; Banks, T. M.; Rubin, B. Structure of human neutrophil collagenase reveals large S1 specificity pocket. Nature Struct. Biol. 1994, 1, 119-123.
12. Cheng, M.; De, B.; Almstead, N. G.; Pikul, S.; Dowty, M. E.; Dietsch, C. R.; Dunaway, C. M.; Gu, F.; Hsieh, L. C.; Janusz, M. J.; Taiwo, Y. O.; Natchus, M. G.; Hudlicky, T.; Mandel, M. Design, Synthesis, and Biological Evaluation of Matrix Metalloproteinase Inhibitors Derived from a Modified Proline Scaffold, J. Med. Chem. 1999, 42, 5426-5436.
13. Matter, H.; Schwab, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Schudok, M.; Thorwat, W.; Schreuder, H.; Brachvogel, V.; Lönze, P.; Weithmann, K. U. Quantitative Structure-Activity Relationship of Human Neutrophil Collagenase (MMP-8) Inhibitors Using Comparative Molecular Field Analysis and X-ray Structure Analysis. J. Med. Chem. 1999, 42, 1908-1920.
14. Natchus, M. G.; Bookland, R. G.; De, B.; Almstead, N. G.; Pikul, S.; Janusz, M. J.; Heitmeyer, S. A.; Hookfin, E. B.; Hsieh, L. C.; Dowty, M. E.; Dietsch, C. R.; Patel, V. S.; Garver, S. M.; Gu, F.; Pokross, M. E.; Mieling, G. E.; Baker, T. R.; Foltz, D. J.; Peng, S. X.; Bornes, D. M.; Strojnowski, M. J.; Taiwo, Y. O. Development of New Hydroxamate Matrix Metalloproteinase Inhibitors Derived from Functionalized 4-Aminoprolines. J. Med. Chem. 2000, 43, 4948-4963.
15. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
16. Baron, M.; Constantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating Optimal Linear PLS Estimation (GOLFE) - An advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct. Act. Relat. 1993, 12, 9-20.
17. Matter, H.; Schwab, W. Affinity and Selectivity of Matrix Metalloproteinase Inhibitors: A Chemometrical Study from the Perspective of Ligands and Proteins. J. Med. Chem. 1999, 42, 4506-4523.
18. Amin, E. A.; Welsh, W. J. Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Models for a Novel Class of Piperazine-Based Stromelysin-1 (MMP-3) Inhibitors: Applying a "Divide and Conquer" Strategy. J. Med. Chem. 2001, 44, 3849-3855.
19. Catalyst, version 4.9 (software package); Accelrys, Inc. (previously known as Molecular Simulations, Inc.): San Diego. CA, 2003, http://www.accelrys. com.
20. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourno, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
21. SYBYL 6.9.1; The Tripos Associates; 1699 S. Hanley Rd., St. Louis, MO.
22. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
23. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ohio, C.; Alagona, G.; Profeta, S., Jr.; Weiner, P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 1984, 106, 765-784.
24. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.
25. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
26. Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
27. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic physicochemical parameters for three-dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
28. Klebe, G. The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. J. Mol. Biol. 1994, 257, 212-235.
29. Wada C. K.; Holms J. H.; Curtin, M. L.; Dai, Y.; Florjancic, A. S.; Garland, R. B.; Guo, Y.; Heyman, H. R.; Stacey, J. R.; Steinman, D. H.; Albert, D. H.; Bouska, J. J.; Elmore, I. N.; Goodfellow, C. L.; Marcotte, P. A.; Tapang, P.; Morgan, D. W.; Michaelides, M. R.; Davidsen, S. K. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 2002, 45, 219-232.
30. Lewis, E. J.; Bishop, J.; Bottomley, K. M. K.; Bradshaw, D.; Brewster, M.; Broadhurst, M. J.; Brown, P. A.; Budd, J. M.; Elliott, L.; Greenham, A. K.; Johnson, W. H.; Nixon, J. S.; Rose, F.; Sutton, B.; Wilson, K. British. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. J. Pharmacol. 1997, 121, 540-546.
31. Fray M. J.; Dickinson, R. P.; Huggins, J. P.; Occleston, N. L. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J. Med. Chem. 2003, 46, 3514-3525.
32. Yamamoto, M.; Tsujishita, H.; Hori, N.; Ohishi, Y.; Inoue, S.; Ikeda, S.; Okada, Y. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J. Med. Chem. 1998, 41, 1209-1217.
33. Fujisawa, T.; Igeta, K.; Odake, S.; Morita, Y.; Yasuda, J.; Morikawa, T. Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model. Bioorg. Med. Chem. 2002, 10, 2569-2581.
34. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a nonpeptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
35. Wall, L.; Talbot, D. C.; Bradbury, P.; Jodrell, D. I. Br. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. J. Cancer. 2004, 90, 800-804.
36. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaninathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
37. Smellie, A.; Teig, S. L.; Tobwin, P. Poling: Promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.
38. Ewing, T.; Kuntz, I. D. Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 1997, 18, 1175-89.
39. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-82.
40. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-97.
41. Senese, C. L.; Hopfinger, A. J. Receptor-Independent 4D-QSAR Analysis of a Set of Norstatine Derived Inhibitors of HIV-1 Protease. J. Chem. Inf. Comput. Sci. 2003, 43 1297-1307.
42. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B.; Albuquerque, M.; Madhav, P. J.; Duraiswami, G. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc. 1997, 119, 10509-10524.